Primary Immunodeficiency Disorder
- SC (Adults and Children ): Dose is administered 1 wk after IGIV dose. Dose is determined by multiplying previous IGIV dose by 1.37, then divide into weekly doses based on frequency of previous treatment. Recommended dose is 100–200 mg/kg/wk.
- IV (Adults and Children ): 300–600 mg (3–6 mL)/kg q 3–4 wk.
Hepatitis A Prophylaxis (IM)
- IM (Adults and Children ): 0.02 mL/kg (for pre-exposure prophylaxis, higher doses—0.06 mL/kg q 4–6 mo are used if exposure will last >3 mo).
Measles Prophylaxis (IM)
- IM (Adults and Children ): 0.25 mL/kg (0.5 mL/kg if immunosuppressed; not to exceed 15 mL).
Immunoglobulin Deficiency (IM)
- IM (Adults and Children ): 1.3 mL/kg initially, then 0.66 mL/kg q 3–4 wk.
Varicella (IM)
- IM (Adults and Children ): 0.6–1.2 mL/kg if varicella zoster immune globulin is unavailable.
Rubella (IM)
- IM (Adults and Children ): 0.55 mL/kg.
Immunodeficiency (IV)
- IV (Adults and Children ): 200–800 mg (4–8 mL)/kg monthly; if response is inadequate, may be given twice monthly.
Idiopathic Thrombocytopenic Purpura
- IV (Adults and Children ): 0.4 g/kg/day for 2–5 days; then 0.4 g/kg single infusion as needed to maintain platelet count of 30,000 cells/mm3 or prevent bleeding; doses up to 0.8–1.0 g/kg may be needed.
- IV (Adults and Children ): Privigen and Gamunex–C1 g/kg daily for 2 consecutive days for a total of 2 g/kg.
Prevention of Bacterial Infections in HIV-Infected Patients, or B cell CLL
- IV (Adults and Children ): 400 mg/kg q 3–4 wk.
Kawasaki Syndrome
- IV (Children ): 400 mg/kg/day for 4 consecutive days or 1–2 g/kg single dose given with aspirin therapy; must be started within 10 days of onset of symptoms.
Chronic Inflammatory Demyelinating Polyneuropathy
- IV (Adults ): 2 g/kg in divided doses over 2–4 consecutive days initially, then 1 g/kg administered over one day (or 0.5 g/kg administered on 2 consecutive days) q 3 wk.